Business
Aclaris Therapeutics Announces Positive Interim Results of Phase 1a Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Supporting Expedited Clinical Development
- Positive Interim Results of Phase 1a Single (SAD) and Multiple Ascending Dose (MAD) Trial Reinforce Potential Best-in-Class Potency Advantage of ATI-052 - ...
About this update from Aclaris Therapeutics, Inc.
[{"type":"image","alt":"Aclaris Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Aclaris Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":126,"url":"https://media.zenfs.com/en/globenewswire.com/863f11ac89f9dbe84886691262d6e9f8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/6F15OlckspEeRRnvMP1sTg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3NjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/863f11ac89f9dbe84886691262d6e9f8","width":300,"height":126}},"lazy":false},{"type":"text","content":"- Positive Interim Results of Phase 1a Single (SAD) and Multiple Ascending Dose (MAD) Trial Reinforce Potential Best-in-Class Potency Advantage of ATI-052 -","length":156,"tagName":"p"},{"type":"text","content":"- Trial Results Support Potential for Extended Dosing of up to Every Three Months -","length":83,"tagName":"p"},{"type":"text","content":"- Initiation of Phase 1b Proof-of-Concept (POC) Trials in Atopic Dermatitis (AD) and Asthma Now Expected in First Quarter of 2026; Planning Underway for Advancement of ATI-052 into Phase 2b Trial in AD in the Second Half of 2026 -","length":230,"tagName":"p"},{"type":"text","content":"- Management to Host a Conference Call to Discuss Update Today at 8:00 AM EST -","length":79,"tagName":"p"},{"type":"text","content":"WAYNE, Pa., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced positive interim results from the first-in-human Phase 1a single (SAD) and multiple ascending dose (MAD) trial of its anti-TSLP/IL-4Rα bispecific antibody ATI-052.","length":392,"tagName":"p"},{"type":"text","content":"“Aclaris has experienced significant momentum across our pipeline over the past few months; consistent with that strong momentum, we are pleased to report positive interim results from our Phase 1a SAD/MAD trial of ATI-052 that exceeded our expectations,” said Dr. Neal Walker, Chief Executive Officer of Aclaris. “ATI-052 demonstrated a strong safety and tolerability profile, dose proportional pharmacokinetic profile, and concentration-dependent pharmacodynamics even at the lowest dose – all of which support its best-in-class potential in a variety of inflammatory and immunological diseases due to its ...